Raechel T. White, PharmD, PhC, BCACP

Incretin therapies have emerged as a promising treatment option with potential benefits for mitigating cardiometabolic side effects associated with antipsychotics; however, clinical trials have often excluded psychiatric populations.

After a failed trial of prazosin, a switch to terazosin was efficacious in reducing the severity and frequency of trauma-related nightmares.